Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 25:12:879.
doi: 10.3332/ecancer.2018.879. eCollection 2018.

High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease

Carolina Alves  1 , Marcella Mesquita  1 , Carolina Silva  1 , Maria Soeiro  1 , Ludhmila Hajjar  1 , Rachel P Riechelmann  1   2
Affiliations

High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease

Carolina Alves et al. Ecancermedicalscience. .

Abstract

Background: Patients with carcinoid syndrome (CS) may present carcinoid heart disease (CHD) but prognostic factors are not entirely understood.

Patients and methods: Retrospective study of patients with metastatic neuroendocrine tumours (NETs) and CS and/or abnormal 24-hour-urinary 5-hydroxiindolacetic acid. CHD was defined as moderate to severe tricuspid or pulmonary regurgitation in the echocardiogram.

Results: The frequency of CHD among 42 patients was 38% (95% confidence interval [CI]: 23%-54%). CHD was associated with higher volume of liver metastases (odds ratio [OR] 13.86, 95% CI: 2.57-74.68, p = 0.002). Time from CS symptoms to NET diagnosis was borderline significant (p = 0.08). When CHD was defined as at least mild tricuspide regurgitation, the frequency of CHD was 45% and it was associated with cardiovascular comorbidities (OR: 6.58, 95% CI: 1.09; 39.78, p = 0.040).

Conclusion: CHD was frequent among patients with CS, significantly associated with high liver tumour burden, and likely linked to the history of cardiovascular disease and longer time of CS.

Keywords: carcinoid heart; carcinoid syndrome; metastases; neuroendocrine tumours.

PubMed Disclaimer

References

    1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534. doi: 10.1016/S1470-2045(17)30110-9. - DOI - PMC - PubMed
    1. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77(2):264–269. doi: 10.1161/01.CIR.77.2.264. - DOI - PubMed
    1. Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. doi: 10.3332/ecancer.2016.662. - DOI - PMC - PubMed
    1. Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol. 1989;63(5):347–352. doi: 10.1016/0002-9149(89)90344-5. - DOI - PubMed
    1. Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288–1304. doi: 10.1016/j.jacc.2016.12.030. - DOI - PubMed

LinkOut - more resources